NASDAQ:AMRN Amarin (AMRN) Stock Forecast, Price & News $0.93 +0.02 (+2.21%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$0.89▼$0.9450-Day Range$0.91▼$1.4352-Week Range$0.89▼$2.23Volume1.42 million shsAverage Volume1.49 million shsMarket Capitalization$373.83 millionP/E RatioN/ADividend YieldN/APrice Target$1.81 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Amarin MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside95.8% Upside$1.81 Price TargetShort InterestHealthy4.09% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.16Based on 5 Articles This WeekInsider TradingAcquiring Shares$312,000 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.22) to ($0.20) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.08 out of 5 starsMedical Sector505th out of 963 stocksPharmaceutical Preparations Industry232nd out of 458 stocks 3.0 Analyst's Opinion Consensus RatingAmarin has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.81, Amarin has a forecasted upside of 95.8% from its current price of $0.93.Amount of Analyst CoverageAmarin has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.09% of the outstanding shares of Amarin have been sold short.Short Interest Ratio / Days to CoverAmarin has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Amarin has recently decreased by 9.54%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAmarin does not currently pay a dividend.Dividend GrowthAmarin does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AMRN. Previous Next 1.6 News and Social Media Coverage News SentimentAmarin has a news sentiment score of -0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Amarin this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for AMRN on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows5 people have added Amarin to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amarin insiders have bought more of their company's stock than they have sold. Specifically, they have bought $312,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.81% of the stock of Amarin is held by insiders.Percentage Held by InstitutionsOnly 25.51% of the stock of Amarin is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Amarin are expected to grow in the coming year, from ($0.22) to ($0.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amarin is -10.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amarin is -10.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmarin has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Amarin (NASDAQ:AMRN) StockAmarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Read More AMRN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMRN Stock News HeadlinesSeptember 22, 2023 | americanbankingnews.comFY2023 EPS Estimates for Amarin Co. plc (NASDAQ:AMRN) Cut by Zacks ResearchSeptember 20, 2023 | finance.yahoo.comAmarin (NASDAQ:AMRN) Is In A Good Position To Deliver On Growth PlansSeptember 24, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.September 12, 2023 | finance.yahoo.comAmarin to Present at the 2023 Cantor Global Healthcare ConferenceAugust 31, 2023 | msn.comAmarin Corp - ADR (AMRN) Price Target Increased by 35.17% to 2.50August 8, 2023 | finance.yahoo.comAmarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in IsraelAugust 7, 2023 | benzinga.comScottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)August 7, 2023 | finanznachrichten.deAmarin Corporation plc: Scottish Medicines Consortium Accepts VAZKEPA (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in ScotlandSeptember 24, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.August 3, 2023 | finance.yahoo.comAmarin (AMRN) Q2 Earnings and Revenues Surpass EstimatesAugust 3, 2023 | finance.yahoo.comAmarin Reports Second Quarter 2023 Financial ResultsAugust 2, 2023 | finanznachrichten.deAmarin Corporation plc: Amarin Reports Second Quarter 2023 Financial ResultsJuly 31, 2023 | finance.yahoo.comAmarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South KoreaJuly 27, 2023 | finance.yahoo.comLatest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) CongressJuly 25, 2023 | finance.yahoo.comAmarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in SpainJuly 21, 2023 | msn.comGoldman Sachs Maintains Amarin Corp - ADR (AMRN) Sell RecommendationJuly 20, 2023 | finanznachrichten.deAmarin Corporation plc: Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick HoltJuly 20, 2023 | seekingalpha.comAmarin appoints Patrick Holt CEOJuly 20, 2023 | msn.comNorthland Capital Markets Maintains Amarin Corp - ADR (AMRN) Market Perform RecommendationJuly 20, 2023 | finance.yahoo.comAmarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick HoltJuly 19, 2023 | finance.yahoo.comAmarin (AMRN) Dips 16% on Layoff Plan & Preliminary Sales MissJuly 19, 2023 | markets.businessinsider.comWhy Are Amarin Shares Plunging Today?July 19, 2023 | msn.comAmarin Tanks as it Plans ReorganizationJuly 18, 2023 | seekingalpha.comAmarin sinks 11% on plan to undergo restructuringJuly 18, 2023 | finanznachrichten.deAmarin Corporation plc: Amarin Appoints Patrick Holt as President and Chief Executive OfficerJuly 18, 2023 | markets.businessinsider.comAmarin Corp Appoints Patrick Holt As President And CEOJuly 18, 2023 | finance.yahoo.comAmarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient Access to VASCEPA®/VAZKEPA® GloballySee More Headlines Receive AMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter. Email Address AMRN Company Calendar Last Earnings8/02/2023Today9/24/2023Next Earnings (Estimated)10/26/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AMRN CUSIPN/A CIK897448 Webwww.amarincorp.com Phone(531) 669-9020FaxN/AEmployees365Year Founded1991Price Target and Rating Average Stock Price Forecast$1.81 High Stock Price Forecast$3.00 Low Stock Price Forecast$1.00 Forecasted Upside/Downside+95.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-105,800,000.00 Net Margins-11.06% Pretax Margin-12.44% Return on Equity-6.56% Return on Assets-4.36% Debt Debt-to-Equity RatioN/A Current Ratio2.61 Quick Ratio1.77 Sales & Book Value Annual Sales$369.19 million Price / Sales1.01 Cash FlowN/A Price / Cash FlowN/A Book Value$1.47 per share Price / Book0.63Miscellaneous Outstanding Shares403,830,000Free Float368,252,000Market Cap$373.83 million OptionableOptionable Beta1.76 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Thomas Charles Reilly (Age 51)Chief Financial Officer Comp: $856.49kDr. Steven B. Ketchum Ph.D. (Age 58)Pres of R&D and Chief Scientific Officer Comp: $991.19kMr. Aaron D. Berg (Age 60)Exec. VP & Pres of U.S. Comp: $913.7kMr. Patrick HoltPres, CEO & DirectorMr. Jordan Zwick (Age 36)Sr. VP of Corp. Bus. Devel. & Investor Relations Ms. Donna PasekSr. VP of HRMr. Laurent AbuafPres of Europe & Sr. VPDr. Nabil AbadirChief Medical Officer of Global Medical AffairsDr. David Keenan Ph.D.Exec. VP of Technical Operations & Pres of EuropeMore ExecutivesKey CompetitorsCOMPASS PathwaysNASDAQ:CMPSArcutis BiotherapeuticsNASDAQ:ARQTLyell ImmunopharmaNASDAQ:LYELEdgewise TherapeuticsNASDAQ:EWTXbioteNASDAQ:BTMDView All CompetitorsInsiders & InstitutionsStadium Capital Management LLCSold 30,468 shares on 8/23/2023Ownership: 0.143%Patrick HoltBought 300,000 shares on 8/16/2023Total: $312,000.00 ($1.04/share)GTS Securities LLCBought 29,776 shares on 8/16/2023Ownership: 0.007%Goldman Sachs Group Inc.Bought 79,676 shares on 8/15/2023Ownership: 0.060%Wells Fargo & Company MNSold 25,723 shares on 8/15/2023Ownership: 0.018%View All Insider TransactionsView All Institutional Transactions AMRN Stock - Frequently Asked Questions Should I buy or sell Amarin stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AMRN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMRN, but not buy additional shares or sell existing shares. View AMRN analyst ratings or view top-rated stocks. What is Amarin's stock price forecast for 2023? 3 equities research analysts have issued twelve-month price targets for Amarin's stock. Their AMRN share price forecasts range from $1.00 to $3.00. On average, they predict the company's share price to reach $1.81 in the next twelve months. This suggests a possible upside of 95.8% from the stock's current price. View analysts price targets for AMRN or view top-rated stocks among Wall Street analysts. How have AMRN shares performed in 2023? Amarin's stock was trading at $1.21 at the start of the year. Since then, AMRN stock has decreased by 23.5% and is now trading at $0.9257. View the best growth stocks for 2023 here. Are investors shorting Amarin? Amarin saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 16,500,000 shares, a drop of 9.5% from the August 15th total of 18,240,000 shares. Based on an average daily volume of 2,450,000 shares, the days-to-cover ratio is currently 6.7 days. View Amarin's Short Interest. When is Amarin's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023. View our AMRN earnings forecast. How were Amarin's earnings last quarter? Amarin Co. plc (NASDAQ:AMRN) issued its quarterly earnings data on Wednesday, August, 2nd. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, hitting the consensus estimate of ($0.04). The biopharmaceutical company had revenue of $80.17 million for the quarter, compared to analyst estimates of $73.40 million. Amarin had a negative net margin of 11.06% and a negative trailing twelve-month return on equity of 6.56%. What is John Thero's approval rating as Amarin's CEO? 43 employees have rated Amarin Chief Executive Officer John Thero on Glassdoor.com. John Thero has an approval rating of 93% among the company's employees. This puts John Thero in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at Amarin to a friend. What other stocks do shareholders of Amarin own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), Alibaba Group (BABA), Tesla (TSLA), Bank of America (BAC), Netflix (NFLX) and Novavax (NVAX). What is Amarin's stock symbol? Amarin trades on the NASDAQ under the ticker symbol "AMRN." Who are Amarin's major shareholders? Amarin's stock is owned by a number of institutional and retail investors. Top institutional shareholders include ExodusPoint Capital Management LP (0.96%), Woodline Partners LP (0.56%), Price Jennifer C. (0.55%), Gratus Capital LLC (0.46%), Acadian Asset Management LLC (0.29%) and AlphaCentric Advisors LLC (0.14%). Insiders that own company stock include David M Stack, John F Thero, Joseph S Zakrzewski, Michael Wayne Kalb, Olsen Per Wold, Patrick Holt and Steven B Ketchum. View institutional ownership trends. How do I buy shares of Amarin? Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Amarin's stock price today? One share of AMRN stock can currently be purchased for approximately $0.93. How much money does Amarin make? Amarin (NASDAQ:AMRN) has a market capitalization of $373.83 million and generates $369.19 million in revenue each year. The biopharmaceutical company earns $-105,800,000.00 in net income (profit) each year or ($0.09) on an earnings per share basis. How many employees does Amarin have? The company employs 365 workers across the globe. Does Amarin have any subsidiaries? The following companies are subsidiares of Amarin: Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharma Inc., Amarin Pharmaceuticals Ireland Limited, Amarin Switzerland GmbH, Amarin UK Limited, Ester Neurosciences, and Ester Neurosciences Limited.Read More How can I contact Amarin? Amarin's mailing address is 77 Sir John Rogerson`s Quay Block C Grand Canal Docklands, Dublin L2, Dublin 2. The official website for the company is www.amarincorp.com. The biopharmaceutical company can be reached via phone at (531) 669-9020 or via email at investor.relations@amarincorp.com. This page (NASDAQ:AMRN) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.